These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M; Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865 [TBL] [Abstract][Full Text] [Related]
7. Contemporary approach to electrical and pharmacological cardioversion of atrial fibrillation. Rajagopalan B; Curtis AB Postgrad Med; 2012 Nov; 124(6):26-35. PubMed ID: 23322136 [TBL] [Abstract][Full Text] [Related]
8. Novel anticoagulants for atrial fibrillation: a critical appraisal. Tzeis S; Andrikopoulos G Angiology; 2012 Apr; 63(3):164-70. PubMed ID: 22007032 [TBL] [Abstract][Full Text] [Related]
9. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583 [TBL] [Abstract][Full Text] [Related]
10. Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: atrial fibrillation type determines the success rate. Derejko P; Polańska M; Chojnowska L; Michałowska I; Wójcik A; Piotrowicz E; Lech A; Kłopotowski M; Baranowski R; Przybylski A; Bilińska M; Sierpiński R; Walczak F; Szumowski L Kardiol Pol; 2013; 71(1):17-24. PubMed ID: 23348529 [TBL] [Abstract][Full Text] [Related]
11. Atrial fibrillation: goals of therapy and management strategies to achieve the goals. Padanilam BJ; Prystowsky EN Med Clin North Am; 2008 Jan; 92(1):217-35, xii-xiii. PubMed ID: 18061006 [TBL] [Abstract][Full Text] [Related]
12. A review of oral anticoagulants in patients with atrial fibrillation. Greenspon AJ Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134 [TBL] [Abstract][Full Text] [Related]
13. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. Van Gelder IC; Hagens VE; Bosker HA; Kingma JH; Kamp O; Kingma T; Said SA; Darmanata JI; Timmermans AJ; Tijssen JG; Crijns HJ; N Engl J Med; 2002 Dec; 347(23):1834-40. PubMed ID: 12466507 [TBL] [Abstract][Full Text] [Related]
14. CHA2DS2-VASc in the prediction of early atrial fibrillation relapses after electrical or pharmacological cardioversion. Falsetti L; Viticchi G; Tarquinio N; Silvestrini M; Capeci W; Balloni A; Catozzo V; Gentile A; Pellegrini F J Cardiovasc Med (Hagerstown); 2014 Aug; 15(8):636-41. PubMed ID: 24978663 [TBL] [Abstract][Full Text] [Related]
15. Management of atrial fibrillation in the elderly. Aronow WS Minerva Med; 2009 Feb; 100(1):3-24. PubMed ID: 19182738 [TBL] [Abstract][Full Text] [Related]
16. Treatment of atrial fibrillation and atrial flutter: Part II. Aronow WS Cardiol Rev; 2008; 16(5):230-9. PubMed ID: 18708824 [TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation. Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640 [TBL] [Abstract][Full Text] [Related]
18. Management of atrial fibrillation in the acute setting. Chenoweth J; Diercks DB Curr Opin Crit Care; 2012 Aug; 18(4):333-40. PubMed ID: 22622515 [TBL] [Abstract][Full Text] [Related]
19. Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation. Trujillo TC; Dobesh PP; Crossley GH; Finks SW Pharmacotherapy; 2019 Jan; 39(1):94-108. PubMed ID: 30548542 [TBL] [Abstract][Full Text] [Related]